

Special Issue

Treatments of Uveal Melanoma

Message from the Guest Editor

The aim of this Special Issue is to emphasise the high-quality research being undertaken into this rare but lethal condition. The scope would cover the early identification of small melanomas, the benefits of early treatments, the advances in visually preserving treatments of the primary tumour and the interventions available to preserve vision in treated patients with ocular side effects. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

- Early identification of uveal melanoma;
- New vision preserving treatments for uveal melanoma;
- Treatments for radiation induced ocular sequelae;
- Prognostication;
- Surveillance;
- Treatment of metastatic disease.

Guest Editor

Dr. Rumana N. Hussain

Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK

Deadline for manuscript submissions

15 October 2025



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/221004

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)